Victory Capital Management
FULC icon

Victory Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Victory Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30,012
Closed -$147K – 2720
2022
Q2 		$147K Buy
30,012
+1,105
+4% +$10.8K ﹤0.01% 2408
2022
Q1 		$278K Buy
+28,907
New +$409K ﹤0.01% 2323
2020
Q2 		– Sell
-8,478
Closed -$102K – 2792
2020
Q1 		$102K Buy
8,478
+4,521
+114% +$72.3K ﹤0.01% 2528
2019
Q4 		$66K Sell
3,957
-7,819
-66% -$74.7K ﹤0.01% 2597
2019
Q3 		$78K Buy
+11,776
New +$130K ﹤0.01% 2520

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Victory Capital Management's FULC Position: Q3 2022 in Review

Victory Capital Management sold out of Fulcrum Therapeutics (FULC) in Q3 2022, closing a stake of 30,012 shares — an estimated $147K sold.

Victory Capital Management first reported a position in FULC in Q3 2019 and held it in 5 quarters. The position peaked at $278K in Q1 2022. 105 funds tracked by Wall St. Rank hold FULC as of Q3 2022.

  • Victory Capital Management reported no remaining Fulcrum Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Victory Capital Management sold 30,012 Fulcrum Therapeutics shares in Q3 2022, an estimated $147K.
  • Victory Capital Management first reported a position in Fulcrum Therapeutics in Q3 2019 and held it in 5 quarters.
  • Victory Capital Management's Fulcrum Therapeutics position peaked at $278K in Q1 2022.
  • 105 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2022.

Based on Victory Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.